PTC Therapeutics reports positive 24-month data for Huntington's disease drug votoplam

Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read

Key Changes

• high

  Company announced positive topline results from 24-month interim analysis of PIVOT-HD extension study evaluating votoplam for Huntington's disease, representing a key clinical milestone for the program.

  Item 8.01 view on EDGAR →
• medium

  PTC held virtual presentation on April 28, 2026 to discuss detailed study results with investors and stakeholders.

  8-K: Press Release verify on EDGAR →
• medium

  Company filed corporate presentation deck containing the 24-month interim analysis data alongside the 8-K disclosure.

  Exhibit 99.2 view on EDGAR →